COVID-19 and Cardiomyopathy: A Systematic Review
Fatemeh Omidi1, Bahareh Hajikhani2, Seyyedeh Neda Kazemi3
1Department of Cardiology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Insights
Sudden cardiac death in adolescents is often linked to cardiomyopathies (CMPs). This study found cardiac injury and CMPs are common in COVID-19 patients, highlighting the need for cardiac monitoring.
Area of Science:
- Cardiology
- Infectious Diseases
- Public Health
Background:
- Cardiomyopathies (CMPs) are a significant cause of sudden adolescent death and heart failure.
- Limited data existed on cardiac complications in COVID-19 patients during the pandemic.
- Investigating the link between COVID-19 and CMPs is crucial for understanding severe outcomes.
Approach:
- A systematic literature search was performed across major databases (PubMed/Medline, Web of Science, Embase) up to August 2020.
- Included 29 articles encompassing 1460 patients diagnosed with COVID-19 and cardiomyopathy.
- Analyzed comorbidities, laboratory findings, and echocardiographic results.
Key Points:
- Hypertension, diabetes, obesity, hyperlipidemia, and ischemic heart disease were common comorbidities.
- Elevated troponin levels were observed in 21.47% of patients.
- All patients exhibited raised D-dimer levels, and varying degrees of Left Ventricular (LV) dysfunction were noted.
Conclusions:
- Cardiac injury and CMPs are frequently observed in patients with COVID-19.
- The findings suggest that cardiac damage should be a key consideration in the management of COVID-19 patients.
- Further research is warranted to elucidate the mechanisms and long-term implications of COVID-19-associated cardiac complications.
Abstract:
Background: Cardiomyopathies (CMPs) due to myocytes involvement are among the leading causes of sudden adolescent death and heart failure. During the COVID-19 pandemic, there are limited data available on cardiac complications in patients with COVID-19, leading to severe outcomes. Methods: We conducted a systematic search in Pubmed/Medline, Web of Science, and Embase databases up to August 2020, for all relevant studies about COVID-19 and CMPs. Results: A total of 29 articles with a total number of 1460 patients were included. Hypertension, diabetes, obesity, hyperlipidemia, and ischemic heart disease were the most reported comorbidities among patients with COVID-19 and cardiomyopathy. In the laboratory findings, 21.47% of patients had increased levels of troponin. Raised D-dimer levels were also reported in all of the patients. Echocardiographic results revealed mild, moderate, and severe Left Ventricular (LV) dysfunction present in 17.13, 11.87, and 10% of patients, respectively. Conclusions: Cardiac injury and CMPs were common conditions in patients with COVID-19. Therefore, it is suggested that cardiac damage be considered in managing patients with COVID-19.
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Myocarditis I: Introduction


